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Background: The causes of ovarian cancer are complex and may be influenced by many factors, including
polymorphism in the microsomal epoxide hydrolase (mEH) gene. Previous work suggests an association between
the Tyr113His mEH polymorphism rs1051740 and susceptibility to ovarian cancer, but the results have been
inconsistent.
Methods: PubMed, EMBASE, Google Scholar, and Chinese National Knowledge Infrastructure databases were
systematically searched to identify relevant studies. A meta-analysis was performed to examine the association
between Tyr113His mEH polymorphism and susceptibility to ovarian cancer. Odds ratios (ORs) and 95% confidence
intervals (CIs) were calculated.
Results: Five studies involving 2,566 cases and 2,839 controls were included. Although the polymorphism did not
affect ovarian cancer risk in the allelic contrast model (OR = 0.99, 95% CI = 0.83-1.17, P = 0.86), the mutant CC
genotype was significantly associated with increased risk in the homozygote comparison (OR = 1.20, 95%
CI = 1.01-1.43, P = 0.04) and recessive genetic models (OR = 1.20, 95% CI = 1.01-1.41, P = 0.03). The wild-type TT
genotype was not associated with higher or lower ovarian cancer risk in the dominant genetic model (OR = 1.04,
95% CI = 0.83-1.29, P = 0.74). These results were robust to sensitivity analysis.
Conclusions: The CC genotype of Tyr113His mEH may confer increased risk of ovarian cancer. These conclusions
should be verified in large and well-designed studies.
Keywords: Meta-analysis, Microsomal epoxide hydrolase, Polymorphism, Ovarian cancerIntroduction
Ovarian cancer is the leading cause of gynecology-
related cancer death, with an estimated 22,240 new cases
and 14,030 deaths in the United States alone in 2013 [1].
Ovarian cancer is difficult to diagnose early, so it is cru-
cial to identify risk factors in order to promote preven-
tion. Unfortunately the etiology of ovarian cancer
remains unclear. Some epidemiological studies suggest
that genetic factors play an important role. Candidate
risk factors include the genes encoding insulin receptor
substrate 1 [2], Lysyl oxidase G473A [3], murine double
minute 2 [4], and progesterone receptor [5].
Another candidate risk factor that has received a lot of
attention is the gene encoding microsomal epoxide
hydrolase (mEH). This gene is overexpressed in ovarian* Correspondence: zhongjianhong66@163.com; xitongpingjia@163.com
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reproduction in any medium, provided the ortissue [6], where it plays a role in estrogen production
[7]. The protein is also a phase II metabolic enzyme that
plays an important role in the activation and detoxifica-
tion of exogenous chemicals, as well as in the metabol-
ism of epoxides and endogenous steroids [8,9]. Since
epoxides are highly reactive oxidative metabolites, mEH
is thought to act on the most toxicologically active forms
of drugs and environmental chemicals. Despite its im-
portant protective function, its net effects on the body
can be complex, since it plays a dual role of
procarcinogen detoxifier and activator [10].
Recently, a number of studies have examined the
possible association between the Tyr113His mEH
(rs1051740) polymorphism and ovarian cancer risk
[11-15], but the results have been inconsistent. Since in-
dividual case–control studies may fail to detect compli-
cated genetic relationships because of small sample size,
we performed a meta-analysis of several publishedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mEH polymorphism on ovarian cancer risk.
Materials and methods
Search strategy
All clinical and experimental case–control studies of
mEH polymorphism and ovarian cancer risk published
through January 31, 2013 were identified through sys-
tematic searches in PubMed, EMBASE, Google Scholar,
and Chinese National Knowledge Infrastructure data-
bases. No language restrictions were imposed. The
search terms used were: mEH; HYL1; EPHX; microsomal
epoxide hydrolase; each of these four terms in combin-
ation with polymorphism, variation, genotype, genetic or
mutation; each of the above terms in combination with
ovarian cancer or carcinoma of ovary. Reference lists of
relevant articles were also manually searched to identify
additional relevant publications.
Inclusion criteria
A study was included in the meta-analysis if it satisfied
the following criteria: (a) it assessed the association be-
tween ovarian cancer and the Tyr113His mEH gene
polymorphism, (b) it used a case–control design, and (c)
it provided sufficient published data for estimating an
odds ratio (OR) with a 95% confidence interval (95%
CI). In the case of multiple studies based on the same
population, we selected the study with the largest num-
ber of participants.
Data extraction
Two authors (JHZ and LQL) independently searched the
literature and identified eligible articles based on the in-
clusion criteria. The following data were extracted: first
author’s family name, year of publication, patient ethni-
city or country, numbers and genotypes of cases and
controls, and Hardy-Weinberg equilibrium (HWE) of
controls. Discrepancies were resolved by consensus.
Only those studies that met the predetermined inclusion
criteria were included.
Statistical methods
The unadjusted odds ratio (OR) with 95% confidence
interval (CI) was used to assess the strength of the asso-
ciation between the Tyr113His mEH polymorphism and
ovarian cancer risk based on the genotype frequencies in
cases and controls. The potential association of different
Tyr113His mEH genotypes with ovarian cancer risk was
examined by comparing the C allele with the T allele,
comparing homozygous genotypes, and applying reces-
sive and dominant genetic models.
All statistical tests for this meta-analysis were
performed using RevMan 5.14 (Cochrane Collaboration)
and Stata 11.0 (StataCorp, College Station, USA). Fixed-effect and random-effect models were used to calculate
pooled ORs. The statistical significance of the pooled
ORs was determined using the Z-test, and P < 0.05 was
considered statistically significant. The assumption of
heterogeneity was evaluated by applying a chi-squared-
based Q-test among the studies. In this approach, the Q
value is defined to be identical to the effect size of the
chi-squared test. P > 0.10 for the Q-test indicates a lack
of heterogeneity and suggests that variability in effect
sizes is larger than that expected from chance alone [16].
In these cases, the fixed-effect model was used to calcu-
late a pooled OR for each study. Otherwise, the random-
effect model was used to calculate pooled ORs. HWE in
the control group was assessed using the asymptotic
test, with P < 0.05 considered significant. Small-study
bias was assessed by Harbord’s modified test [17]. As
much as possible, the meta-analyis was carried out
according to the PRISMA guidelines [18].
Results
Description of studies
A total of 115 potentially relevant publications published
through January 31, 2013 were systematically identified
in the PubMed, EMBASE, Google Scholar, and Chinese
National Knowledge Infrastructure databases. Of these,
we excluded 32 studies based on review of the titles and
abstracts because they did not focus on the association
of mEH polymorphism and ovarian cancer risk, or they
did not include a control group (n = 5). In the end, only
five studies [11-15] involving 2,566 cases and 2,839 con-
trols were found to satisfy the inclusion criteria and
included in the meta-analysis (Figure 1). Detailed char-
acteristics of the five studies are listed in Table 1. Partici-
pants in four studies [11,12,14,15] were Caucasian, while
those in the remaining study [13] were Chinese. Geno-
type distribution in controls did not show HWE in two
studies [12,13]. We failed to find additional eligible stud-
ies when we repeated our systematic literature search
procedure in May 2013.
One study [12] did not report histological subtype data
in detail. However, it provided the OR and 95% CI based
on allelic contrast. Three studies [11,13,15] described
the histological data in detail, and the remaining study
[14] did not mention histological subtype at all.
One of the included studies [11] reported that the
polymerase chain reaction restriction fragment length
polymorphism (PCR-RFLP) genotyping method could
lead to incorrect classification of Tyr/His heterozy-
gotes as His/His homozygotes. Among the five in-
cluded studies, only one [14] used this approach,
whereas the others [11-13,15] used allele-specific PCR.
Therefore we conducted sensitivity analysis based on
genotyping method to assess the robustness of our
meta-analysis results.
Figure 1 Flow chart of study selection. mEH, microsomal epoxide hydrolase.
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Table 2 shows the summary ORs for the Tyr113His
mEH polymorphism and ovarian cancer risk on the
basis of 2,566 cases and 2,839 controls. Calculation of
overall OR in the total population using the random-
effect model showed that the C allele did not influence
risk of ovarian cancer based on allelic contrast (OR =
0.99, 95% CI = 0.83-1.17, P = 0.86; I2 = 58%) (Figure 2).
However, the variant CC genotype was associated with
increased risk of ovarian cancer relative to the TT
genotype (OR = 1.20, 95% CI = 1.01-1.43, P = 0.04) and
to the TT + TC genotypes (OR = 1.20, 95% CI = 1.01-
1.41, P = 0.03). In contrast, the wild-type TT genotype
was not associated with higher or lower ovarian cancer
risk than was the CC + TC genotype (OR = 1.04, 95%
CI = 0.83-1.29, P = 0.74).Table 1 Principal characteristics of studies included in the me
Study Country Ethnicity Genotyping
method
PH
Baxter 200211 UK Caucasian Allele-specific PCR 0.2
Goode 201112 US and Australia Caucasian Allele-specific PCR 0.0
Kang 200413 China Chinese Allele-specific PCR <0
Lancaster 199614 US Caucasian PCR-RFLP 0.6
Spurdle 200115 Australia Caucasian Allele-specific PCR 0.2Small-study bias tests showed no significant bias (P= 0.054;
Additional file 1: Figure S1).Subgroup analysis by ethnicity
Chinese ethnicity
After stratification for ethnicity, we observed that in the
Chinese population of 86 cases and 174 controls [13],
mEH polymorphism was not associated with increased
or decreased risk of ovarian cancer based on the C allele,
homozygote comparison, or recessive and dominant
genetic models (C allele, OR = 0.83, 95% CI = 0.58-1.20,
P = 0.32; homozygotes, OR = 0.78, 95% CI = 0.42-1.46,
P = 0.44; recessive model, OR = 0.77, 95% CI = 0.45-1.30,
P = 0.32; dominant model, OR = 1.13, 95% CI = 0.65-





No. of cases No. of controls
TT TC CC TT TC CC
37 0.65 291/257 142 114 35 129 100 28
34 0.03 1571/2046 767 599 205 1030 815 201
.001 0.32 86/174 27 26 33 50 46 78
26 0.01 73/75 47 17 9 31 33 11
68 0.63 545/287 255 233 57 142 114 31




OR [95% CI] Z (P
value)
Heterogeneity of study design Analysis
modelχ2 df (P value) I2
Total (2566 cases, 2839 controls)
C-allele vs. T-allele 0.99 [0.83, 1.17] 0.17 (0.86) 9.42 4 (0.05) 58% Random
CC vs. TT 1.20 [1.01, 1.43] 2.05 (0.04) 6.21 4 (0.18) 36% Fixed
CC vs. TT + TC 1.20 [1.01, 1.41] 2.11 (0.03) 6.04 4 (0.20) 34% Fixed
TT vs. CC + TC 1.04 [0.83, 1.29] 0.33 (0.74) 9.05 4 (0.06) 56% Random
Caucasian (2480 cases, 2665 controls)
C-allele vs. T-allele 1.01 [0.85, 1.21] 0.13 (0.89) 7.57 3 (0.06) 60% Random
CC vs. TT 1.25 [1.04, 1.50] 2.36 (0.02) 4.22 3 (0.24) 29% Fixed
CC vs. TT + TC 1.26 [1.05, 1.50] 2.56 (0.01) 2.99 3 (0.39) 0% Fixed
TT vs. CC + TC 1.04 [0.80, 1.34] 0.28 (0.78) 8.73 3 (0.03) 66% Random
Chinese (86 cases, 174 controls)
C-allele vs. T-allele 0.83 [0.58, 1.20] 0.99 (0.32)
CC vs. TT 0.78 [0.42, 1.46] 0.77 (0.44)
CC vs. TT + TC 0.77 [0.45, 1.30] 0.99 (0.32)
TT vs. CC + TC 1.13 [0.65, 1.99] 0.44 (0.66)
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Analysis of the Caucasian participants in four studies
[11,12,14,15] gave results similar to those obtained with
the total population (Table 2).Subgroup analysis by histological subtype of ovarian
cancer
The first subtype analysis was based on three studies
with 922 cases and 718 controls [11,13,15]. Meta-
analysis showed that individuals with the C allele had
significantly reduced risk of endometrioid/clear cell
ovarian cancer (OR = 0.54, 95% CI 0.42-0.70, P < 0.001).
At the same time, the homozygous CC genotype signifi-
cantly increased the risk of mucinous ovarian cancer
relative to the TT genotype (OR = 23.53, 95% CI 9.40-
58.93, P < 0.001). Significant associations were not
detected for comparisons of other genotypes and cancer
subtypes (Table 3).Figure 2 Forest plots describing the association of Tyr113His mEH poThe second subtype analysis was based on one study
involving 1571 cases and 2046 controls [12]. Logistic re-
gression analysis of genotype revealed that the C allele
increased serous ovarian cancer risk (OR = 1.17, 95% CI
1.04-1.32, P = 0.01). The same allele did not, however, in-
crease or decrease the risk of other types of ovarian
cancer.
Sensitivity analysis
Sensitivity analysis was carried out to assess the robust-
ness of the meta-analysis results to genotyping method,
given that one study [14] used PCR-RFLP, which may in-
correctly classify Tyr/His heterozygotes as His/His ho-
mozygotes [11]. After excluding the PCR-RFLP study
[14], meta-analysis showed that risk of ovarian cancer
tended to be higher in the presence of the C allele
according to allelic contrast (OR = 1.09, 95% CI 1.00-
1.18, P = 0.06). The CC genotype was associated with in-
creased risk of ovarian cancer both by homozygouslymorphism with ovarian cancer (C-allele vs. T-allele).




OR [95% CI] Z (P value) Heterogeneity of study design Analysis
modelχ2 df (P value) I2
Serous (441 cases, 718 controls)
C-allele vs. T-allele 0.87 [0.72, 1.06] 1.39 (0.16) 4.25 2 (0.12) 53% Fixed
CC vs. TT 0.89 [0.60, 1.33] 0.56 (0.58) 1.85 2 (0.40) 0% Fixed
CC vs. TT + TC 0.85 [0.59, 1.23] 0.87 (0.38) 1.13 2 (0.57) 0% Fixed
TT vs. CC + TC 0.99 [0.78, 1.27] 0.06 (0.95) 1.09 2 (0.58) 0% Fixed
Endometrioid and clear cell (212 cases, 718 controls)
C-allele vs. T-allele 0.54 [0.42, 0.70] 4.67 (<0.001) 0.30 2 (0.86) 0% Fixed
CC vs. TT 1.30 [0.56, 3.01] 0.62 (0.54) 7.36 2 (0.03) 73% Random
CC vs. TT + TC 1.33 [0.65, 2.73] 0.78 (0.43) 6.26 2 (0.04) 68% Random
TT vs. CC + TC 0.88 [0.65, 1.20] 0.78 (0.43) 4.03 2 (0.13) 50% Fixed
Mucinous (70 cases, 544 controls)
C-allele vs. T-allele 1.08 [0.74, 1.58] 0.40 (0.69) 0.94 1 (0.33) 0% Fixed
CC vs. TT 23.53 [9.40, 58.93] 6.74 (<0.001) 0.41 1 (0.52) 0% Fixed
CC vs. TT + TC 0.77 [0.32, 1.86] 0.57 (0.57) 0.13 1 (0.72) 0% Fixed
TT vs. CC + TC 0.79 [0.48, 1.31] 0.90 (0.37) 0.98 1 (0.32) 0% Fixed
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by recessive contrast (OR = 1.23, 95% CI 1.03-1.47, P =
0.02). In contrast, the TT genotype was not associated
with higher or lower ovarian cancer risk based on dom-
inant contrast (OR = 0.94, 95% CI = 0.84-1.05, P = 0.29)
(Table 4).
Discussion
Activity of mEH is critical to the metabolism of xenobi-
otics and procarcinogens that may be involved in initiat-
ing cancers such as ovarian cancer. This meta-analysis
aimed to evaluate the hypothesis that mEH polymorph-
ism, by altering xenobiotic metabolism, may affect risk
of developing ovarian cancer. The results suggest that in
the total population and among Caucasians, although
not necessarily among Asians, the CC genotype of
Tyr113His mEH (rs1051740) is a risk factor of ovarian
cancer according to homozygous and recessive contrast.
These results were robust to sensitivity analysis in which
one study [14] using PCR-RFLP instead of allele-specific




OR [95% CI] Z (P
value)
C-allele vs. T-allele 1.09 [1.00, 1.18] 1.91 (0.06)
CC vs. TT 1.21 [1.02, 1.43] 2.22 (0.03)
CC vs. TT + TC 1.23 [1.03, 1.47] 2.30 (0.02)
TT vs. CC + TC 0.94 [0.84, 1.05] 1.07 (0.29)determine whether particular mEH genotypes affect risk
of particular histological subtypes of ovarian cancer.
The Tyr113His mEH polymorphism has been exten-
sively investigated for its potential involvement in vari-
ous types of cancers, such as colorectal cancer [19], lung
and upper digestive tract cancer [20], esophageal carcin-
oma [21], and hepatocellular carcinoma [22]. Most of
these studies, however, have shown that the polymorph-
ism is not a risk factor, except in the case of hepatocellu-
lar carcinoma [22]. The present study finds compelling
evidence that the homozygous mEH CC genotype may
increase ovarian cancer risk. Thus, Tyr113His mEH
polymorphism may play an important role in the devel-
opment of at least two common cancers.
Patients with different histological subtypes of ovarian
cancer may have different prognoses [23,24], making it im-
portant to understand whether genetic risk applies differ-
ently to particular subtypes. Unfortunately this question
could not be adequately addressed because most included
studies did not report detailed genotype data for different
subtypes. Nevertheless, four [11-13,15] of the five includede-specific PCR as the genotyping method (2493 cases and
Heterogeneity of study design Analysis
modelχ2 df (P value) I2
2.44 3 (0.49) 0% Fixed
5.40 3 (0.14) 44% Fixed
3.62 3 (0.31) 17% Fixed
0.53 3 (0.91) 0% Fixed
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subtypes. Among these four studies, two demonstrated
that the TT genotype was associated with a decreased risk
of endometrioid [15] and serous [11] ovarian cancer. Our
meta-analyses based on three studies [11,13,15] involving
922 cases and 718 controls found that the C allele signifi-
cantly decreased endometrioid/clear cell ovarian cancer
risk (Table 3). At the same time, a single study with 1571
cases and 2046 controls [12] showed that the C allele sig-
nificantly increased serous ovarian cancer risk. Unfortu-
nately the single large study [12] did not describe
histological subtype data in detail, so it could not be com-
bined in a meta-analysis with the other three [11,13,15].
Small sample size may explain the discrepancy among the
studies. Large, well-designed cohort studies examining the
genetic susceptibility of different histological subtypes of
ovarian cancer are needed.
The causes of ovarian cancer appear to be complex,
involving multiple inherited [25-27], environmental
[28,29] and acquired factors [30,31]. While mEH poly-
morphism may participate directly in influencing risk of
ovarian cancer, it may also do so through interactions
with other genes or with the environment. For example,
one study [20] found cigarette smoking to be associated
not only with increased risk of lung cancer but also with
increased likelihood of mEH polymorphism. Arguing
against this possibility, two studies [12,15] in the present
meta-analysis failed to find evidence of synergistic inter-
actions between alcohol or tobacco use and mEH poly-
morphism on risk of ovarian cancer. The remaining
three included studies [11,13,14] did not explore gene-
environment or gene-gene interactions. Future studies
should examine these interactions in detail, especially
given the complexity of ovarian cancer risk factors.
The 113His codon variant is relatively common in the
mEH gene, but allele frequency differs significantly among
ethnicities. For example, the frequency of the homozygous
CC genotype (His113His) is approximately 12% in
Caucasians but 40% in Chinese (Table 1). These data are in
line with other studies [32,33] showing that the frequency
of the His113His variant is greatest in the Asian population
(18-42%) and intermediate in the European population
(about 10%). Surprisingly, despite its higher frequency in
Asians, we did not find any association between the CC
genotype or C allele and risk of ovarian cancer in our
Chinese ethnic subgroup analysis. In contrast, meta-
analysis of all five included studies, with a total participant
population that was 95% Caucasian, showed the CC geno-
type to be a risk factor, and the largest included study [12],
involving Caucasians, indicated an association between the
C allele and increased risk of serous ovarian cancer. Future
work should examine carefully whether the mEH poly-
morphism affects risk of ovarian cancer differently in dif-
ferent ethnicities. It may be, for example, that the C allelenormally increases cancer risk, as observed here in
Caucasians, but no longer in Asians because of compen-
satory mutations with the population could not support
such a high frequency of the risk-bearing allele.
The strengths of this meta-analysis include the large
number of subjects investigated and the attempt to provide
a complete picture taking in account ethnicity, genotyping
method and histological subtype of ovarian cancer. How-
ever, our review also has several limitations. First, although
we included clinical and experimental studies in both Eng-
lish and Chinese in order to avoid local literature bias [34],
the number of included studies was quite small. We were
unable to increase this number even after systematically
searching the databases four months after the original
searches. Thus selective publication bias may exist. Second,
the results may be affected by additional confounding fac-
tors, such as tumor status, age or gender, but most studies
either did not report these baseline data or aggregated
them in different ways, making it impossible to include
them in the meta-analysis. In addition, the vast majority
(95.2%) of data may came from Caucasian populations.
The numbers of Chinese were relatively small (4.8%).
Therefore, the results with Chinese subjects should be
interpreted with caution, and future studies on Chinese
and African populations should evaluate the ethnicity-
specific effects of the mEH polymorphism observed here.
In fact, future studies should be more careful about includ-
ing ethnicity as a confounder variable, since some of the
included studies from the US and UK did not report this
in detail, potentially leading us to overestimate the propor-
tion of Caucasians in our study population. Finally, al-
though the CC genotype was significantly associated with
an increased risk of ovarian cancer compared to the TT
genotype or TT + TC genotypes, the 95% CI is near 1,
suggesting that the association borders on nonsignificance.
Given that the meta-analysis involved more than 5,000
cases and controls altogether, this finding suggests that the
effects of mEH risk are likely to be small and modulated by
interactions with other genes or the environment.
Implications for future practice and study: This meta-
analysis suggests that the mutant CC genotype of
Tyr113His mEH may be associated with increased risk of
ovarian cancer. However, since this meta-analysis included
few studies from non-Caucasian populations, large, well-
designed studies in Asian and African populations are
warranted to re-evaluate these associations. Our findings
also highlight the need for larger, well-designed studies that
take into account histological subtype as well as clinically
relevant outcomes like overall survival and recurrence rate.Additional file
Additional file 1: Figure S1. Small-study bias tests.
Zhong et al. Journal of Ovarian Research 2013, 6:40 Page 7 of 7
http://www.ovarianresearch.com/content/6/1/40Abbreviations
HWE: Hardy-weinberg equilibrium of controls; PCR: Polymerase chain
reaction; RFLP: Restriction fragment length polymorphism.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ZJH contributed to study conception and design. ZJH and ZZM searched the
databases and extracted data. ZJH performed all statistical analysis. ZJH and
LLQ drafted the manuscript. All authors read and approved the final
manuscript.
Acknowledgments
The authors thank Dr Armando Chapin Rodríguez for his language editing,
which substantially improved the quality of the manuscript. This work was
supported by the Self-raised Scientific Research Fund of the Ministry of
Health of Guangxi Province (Project No: Z2012345) to ZJH.
Received: 29 March 2013 Accepted: 3 June 2013
Published: 6 June 2013
References
1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin
2013, 63:11–30.
2. Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Paluch-Shimon S, et
al: A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing
Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2
Mutation Carriers. Cancer Epidemiol Biomarkers Prev 2012, 21:1362–1370.
3. Wu J, Cai C, Tong D, Hou H: Lysyl Oxidase G473A Polymorphism Is
Associated with Increased Risk of Ovarian Cancer. Genet Test Mol
Biomarkers 2012, 16:915–919.
4. Ma YY, Guan TP, Yao HB, Yu S, Chen LG, Xia YJ, He XJ, Wang HJ, Jiang XT,
Tao HQ: The MDM2 309T > G Polymorphism and Ovarian Cancer Risk: A
Meta-Analysis of 1534 Cases and 2211 Controls. PLoS One 2013, 8:e55019.
5. Chaudhary S, Panda AK, Mishra DR, Mishra SK: Association of +331G/A PgR
Polymorphism with Susceptibility to Female Reproductive Cancer:
Evidence from a Meta-Analysis. PLoS One 2013, 8:e53308.
6. Dannan GA, Guengerich FP: Immunochemical comparison and
quantitation of microsomal flavin-containing monooxygenases in various
hog, mouse, rat, rabbit, dog, and human tissues. Mol Pharmacol 1982,
22:787–794.
7. Hattori N, Fujiwara H, Maeda M, Fujii S, Ueda M: Epoxide hydrolase affects
estrogen production in the human ovary. Endocrinology 2000,
141:3353–3365.
8. Newman JW, Morisseau C, Hammock BD: Epoxide hydrolases: their roles
and interactions with lipid metabolism. Prog Lipid Res 2005, 44:1–51.
9. Fretland AJ, Omiecinski CJ: Epoxide hydrolases: biochemistry and
molecular biology. Chem Biol Interact 2000, 129:41–59.
10. Shou M, Gonzalez FJ, Gelboin HV: Stereoselective epoxidation and
hydration at the K-region of polycyclic aromatic hydrocarbons by
cDNA-expressed cytochromes P450 1A1, 1A2, and epoxide hydrolase.
Biochemistry 1996, 35:15807–15813.
11. Baxter SW, Choong DY, Campbell IG: Microsomal epoxide hydrolase
polymorphism and susceptibility to ovarian cancer. Cancer Lett 2002,
177:75–81.
12. Goode EL, White KL, Vierkant RA, Phelan CM, Cunningham JM, Schildkraut
JM, Berchuck A, Larson MC, Fridley BL, Olson JE, Webb PM, Chen X, Beesley
J, Chenevix-Trench G, Sellers TA: Ovarian Cancer Association Consortium;
Australian Ovarian Cancer Study Group: Xenobiotic-Metabolizing gene
polymorphisms and ovarian cancer risk. Mol Carcinog 2011, 50:397–402.
13. Kang S, Duan LH, Li Y, Song JF, Zhang JH: [Relation Between microsomal
epoxide hydrolase polymorphism and susceptibility to ovarian epithelial
cancer]. Zhonghua Fu Chan Ke Za Zhi 2004, 39:556–557.
14. Lancaster JM, Brownlee HA, Bell DA, Futreal PA, Marks JR, Berchuck A,
Wiseman RW, Taylor JA: Microsomal epoxide hydrolase polymorphism as
a risk factor for ovarian cancer. Mol Carcinog 1996, 17:160–162.
15. Spurdle AB, Purdie DM, Webb PM, Chen X, Green A, Chenevix-Trench G:
The microsomal epoxide hydrolase Tyr113His polymorphism: association
with risk of ovarian cancer. Mol Carcinog 2001, 30:71–78.16. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency
in meta-analyses. BMJ 2003, 327:557–560.
17. Harbord RM, Egger M, Sterne JA: A modified test for small-study effects in
meta-analyses of controlled trials with binary endpoints. Stat Med 2006,
25:3443–3457.
18. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke
M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting
systematic reviews and meta-analyses of studies that evaluate health
care interventions: explanation and elaboration. PLoS Med 2009, 6:
e1000100.
19. Liu F, Yuan D, Wei Y, Wang W, Yan L, Wen T, Xu M, Yang J, Li B: Systematic
Review and Meta-Analysis of the Relationship between EPHX1
Polymorphisms and Colorectal Cancer Risk. PLoS One 2012, 7:e43821.
20. Li X, Hu Z, Qu X, Zhu J, Li L, Ring BZ, Su L: Putative EPHX1 enzyme activity
is related with risk of lung and upper aerodigestive tract cancers: a
comprehensive meta-analysis. PLoS One 2011, 6:e14749.
21. Dura P, Bregitha CV, Te Morsche RH, Roelofs HM, Kristinsson JO, Wobbes T,
Witteman BJ, Tan AC, Drenth JP, Peters WH: EPHX1 polymorphisms do not
modify esophageal carcinoma susceptibility in Dutch Caucasians. Oncol
Rep 2012, 27:1710–1716.
22. Zhong JH, Xiang BD, Ma L, You XM, Li LQ, Xie GS: Meta-analysis of
microsomal epoxide hydrolase gene polymorphism and risk of
hepatocellular carcinoma. PLoS One 2013, 8:e57064.
23. Pils D, Hager G, Tong D, Aust S, Heinze G, Kohl M, Schuster E, Wolf A,
Sehouli J, Braicu I, Vergote I, Cadron I, Mahner S, Hofstetter G, Speiser P,
Zeillinger R: Validating the impact of a molecular subtype in ovarian
cancer on outcomes: a study of the OVCAD Consortium. Cancer Sci 2012,
103:1334–1341.
24. Bolton KL, Ganda C, Berchuck A, Pharaoh PD, Gayther SA: Role of common
genetic variants in ovarian cancer susceptibility and outcome: progress
to date from the Ovarian Cancer Association Consortium (OCAC). J Intern
Med 2012, 271:366–378.
25. Nelson HD, Huffman LH, Fu R, Harris EL: Genetic risk assessment and BRCA
mutation testing for breast and ovarian cancer susceptibility: systematic
evidence review for the U.S. Preventive Services Task Force. Ann Intern
Med 2005, 143:362–379.
26. Gulden C, Olopade OI: Risk assessment and genetic testing for ovarian
cancer. AJR Am J Roentgenol 2010, 194:309–310.
27. Fasching PA, Gayther S, Pearce L, Schildkraut JM, Goode E, Thiel F,
Chenevix-Trench G, Chang-Claude J, Wang-Gohrke S, Ramus S, Pharoah P,
Berchuck A, OCAC (Ovarian Cancer Association Consortium): Role of
genetic polymorphisms and ovarian cancer susceptibility. Mol Oncol
2009, 3(2):171–181.
28. Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM: Does smoking
increase risk of ovarian cancer? A systematic review. Gynecol Oncol 2006,
103:1122–1129.
29. Hunn J, Rodriguez GC: Ovarian cancer: etiology, risk factors, and
epidemiology. Clin Obstet Gynecol 2012, 55:3–23.
30. Beral V, Doll R, Hermon C, Peto R, Reeves G: Ovarian cancer and oral
contraceptives: collaborative reanalysis of data from 45 epidemiological
studies including 23,257 women with ovarian cancer and 87,303
controls. Lancet 2008, 371:303–314.
31. Murphy MA, Trabert B, Yang HP, Park Y, Brinton LA, Hartge P, Sherman ME,
Hollenbeck A, Wentzensen N: Non-steroidal anti-inflammatory drug use
and ovarian cancer risk: findings from the NIH-AARP Diet and Health
Study and systematic review. Cancer Causes Control 2012, 23:1839–1852.
32. Pinarbasi H, Silig Y, Pinarbasi E: Microsomal epoxide hydrolase
polymorphisms. Mol Med Report. 2010, 3:723–727.
33. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y: EPHX1 polymorphisms
and the risk of lung cancer: a HuGE review. Epidemiology 2006, 17:89–99.
34. Pan Z, Trikalinos TA, Kavvoura FK, Lau J, Ioannidis JP: Local literature bias in
genetic epidemiology: an empirical evaluation of the Chinese literature.
PLoS Med 2005, 2:e334.
doi:10.1186/1757-2215-6-40
Cite this article as: Zhong et al.: mEH Tyr113His polymorphism and the
risk of ovarian cancer development. Journal of Ovarian Research 2013
6:40.
